Urologix, Inc. (ULGX) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Urologix, Inc. (ULGX) trades at $0.0001 with AI Score 43/100 (Grade C). Urologix, Inc. is a medical device company specializing in minimally invasive treatments for benign prostatic hyperplasia (BPH). Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for ULGX: ULGX does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates ULGX against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
ULGX: 1/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Urologix, Inc. (ULGX) Healthcare & Pipeline Overview
Urologix, Inc. is a leader in developing minimally invasive medical devices for treating benign prostatic hyperplasia (BPH), leveraging innovative technologies like Cooled ThermoTherapy and Prostiva RF Therapy to enhance patient comfort and outcomes in urological care.
What Is the Investment Thesis for ULGX?
Urologix, Inc. presents a unique investment thesis centered on its specialized focus in the urology sector, particularly in treating benign prostatic hyperplasia (BPH). The company's innovative products, such as Cooled ThermoTherapy and Prostiva RF Therapy, leverage advanced technology to enhance treatment efficacy and patient comfort, providing a competitive edge in a growing market. The global market for BPH treatments is projected to expand significantly, driven by an aging population and increasing prevalence of urological disorders. Urologix's existing intellectual property and established market presence position it well to capitalize on this growth. However, potential investors should be aware of the company's financial challenges, including a negative profit margin of -53.4% and a minimal market capitalization of $2,182, indicating significant financial distress. Monitoring future financial filings and strategic initiatives will be crucial for assessing the company's recovery potential and long-term viability.
Based on FMP financials and quantitative analysis
ULGX Key Highlights
Market Cap: $0.00B indicating a distressed financial position.
- Profit Margin: -53.4%, reflecting ongoing financial challenges.
- Gross Margin: 42.8%, which is above the industry average, indicating potential for profitability if revenues increase.
- Beta: -80.29, suggesting low correlation with market movements, which may appeal to certain risk-averse investors.
- No dividend yield, reflecting the company's focus on reinvestment rather than returning cash to shareholders.
Who Are ULGX's Competitors?
ULGX is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| CNVIF Conavi Medical Corp. | $0.13 | -1.19% | $11.4M | 66 |
| VPTDF VentriPoint Diagnostics Ltd. | $0.07 | -4.02% | $13.8M | 62 |
| LHDX Lucira Health, Inc. | $0.45 | +0.00% | $18.4M | 64 |
| PLSM PLSM | $2.96 | -1.66% | $19.3M | 60 |
| PYNKF Perimeter Medical Imaging AI, Inc. | $0.27 | -1.08% | $24.6M | 73 |
| RDGL Vivos Inc. | $0.05 | -5.33% | $26.5M | 61 |
| NVYTF Novacyt S.A. | $0.48 | -0.00% | $34.8M | 61 |
| DNAY Codex DNA, Inc. | $1.30 | +8.33% | $38.3M | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are ULGX's Key Strengths?
Innovative product offerings tailored for BPH treatment.
- Strong intellectual property portfolio.
- Established presence in the urology market.
- Commitment to improving patient comfort and outcomes.
What Are ULGX's Weaknesses?
Negative profit margin indicating financial distress.
- Limited market capitalization restricting growth potential.
- Dependence on a narrow product line focused on BPH.
- Challenges in scaling operations due to financial constraints.
What Are the Key Risks for ULGX?
Financial-distress signal — its Altman Z-Score of -34.44 sits in the distress zone (elevated bankruptcy risk).
What Are the Growth Opportunities for ULGX?
- Expansion of Product Offerings: Urologix has the potential to expand its product line to include additional minimally invasive treatments for other urological conditions. The global market for urological devices is projected to reach $45 billion by 2027, presenting significant growth opportunities. By leveraging its existing technologies and expertise, Urologix could capture a larger share of this burgeoning market, enhancing its revenue streams.
- Geographic Market Expansion: Urologix could explore international markets to increase its footprint. Currently focused on the U.S. market, entering regions with growing healthcare infrastructure, such as Asia-Pacific and Latin America, could provide substantial growth. The global urology market is expected to grow at a CAGR of 6.5% through 2025, driven by increasing demand for advanced medical solutions.
- Strategic Partnerships: Collaborating with healthcare providers and institutions could enhance Urologix's market reach and credibility. Forming alliances with hospitals and clinics could facilitate product adoption and increase sales. Such partnerships could also lead to co-development opportunities, expanding the company's offerings and market presence.
- Technological Advancements: Continued investment in research and development will enable Urologix to innovate further and improve its existing products. By enhancing the efficacy and comfort of its treatments, Urologix can differentiate itself in a competitive market. The focus on R&D is crucial as the medical device industry increasingly relies on technological advancements to meet patient needs.
- Regulatory Approvals and Clinical Trials: Successfully navigating the regulatory landscape and conducting clinical trials for new products can serve as a catalyst for growth. Gaining approval for new therapies can open new revenue streams and enhance Urologix's market position. The company should prioritize compliance and invest in robust clinical trials to validate the safety and efficacy of its innovations.
What Threats Does ULGX Face?
- Intense competition from established medical device companies.
- Regulatory hurdles impacting product development timelines.
- Market volatility affecting funding and investment opportunities.
- Economic downturns leading to reduced healthcare spending.
What Are ULGX's Competitive Advantages?
- Proprietary technologies that enhance treatment efficacy and patient comfort.
- Established brand recognition in the urology medical device market.
- Strong intellectual property portfolio protecting innovations.
- Focus on minimally invasive procedures, appealing to patients and providers.
- Commitment to research and development fostering continuous innovation.
What Does ULGX Do?
Established in 1991 and headquartered in Minneapolis, Minnesota, Urologix, Inc. specializes in the development, production, promotion, and distribution of minimally invasive medical devices across the United States. The company has carved a niche in the healthcare sector by focusing on innovative solutions that target the treatment of obstructions and related symptoms caused by benign prostatic hyperplasia (BPH). Urologix's flagship offerings include Cooled ThermoTherapy, which utilizes microwave energy combined with a cooling mechanism to protect healthy tissues while effectively targeting problematic areas. This approach not only enhances treatment efficacy but also significantly improves patient comfort during procedures. Additionally, the Prostiva RF Therapy System directs radio frequency energy into the prostate gland, effectively eliminating problematic prostatic tissue and alleviating urethral constriction associated with BPH. Urologix, Inc. serves a diverse clientele, including healthcare professionals and patients, positioning itself as a trusted provider in the urology space. Over the years, the company has focused on expanding its product portfolio and enhancing its technological capabilities, aiming to address the growing demand for effective and comfortable treatment options in urological care. Despite facing challenges in the competitive landscape, Urologix remains committed to innovation and improving patient outcomes, making it a noteworthy player in the medical device industry.
What Products and Services Does ULGX Offer?
- Develops minimally invasive medical devices for urological conditions.
- Specializes in treatments for benign prostatic hyperplasia (BPH).
- Offers Cooled ThermoTherapy and Prostiva RF Therapy systems.
- Focuses on improving patient comfort and treatment outcomes.
- Promotes products to healthcare professionals and patients.
- Engages in research and development to innovate in the urology space.
How Does ULGX Make Money?
- Generates revenue through the sale of medical devices and treatment systems.
- Focuses on direct sales to healthcare providers and institutions.
- Invests in research and development to enhance product offerings.
- Utilizes marketing strategies to promote awareness of its solutions.
- Engages in partnerships to expand distribution and market reach.
What Industry Does ULGX Operate In?
The medical device industry, particularly in the urology segment, is witnessing significant growth due to increasing awareness of urological disorders and advancements in minimally invasive technologies. The global market for BPH treatments is expected to grow substantially, driven by an aging population and rising healthcare expenditures. Urologix, Inc. is strategically positioned within this expanding market, focusing on innovative solutions that cater to the specific needs of patients suffering from BPH. The competitive landscape includes several players, but Urologix's proprietary technologies and focus on patient comfort set it apart from traditional treatment methods, enhancing its market positioning.
Who Are ULGX's Key Customers?
- Healthcare professionals specializing in urology.
- Hospitals and clinics providing urological care.
- Patients suffering from benign prostatic hyperplasia (BPH).
- Medical institutions seeking innovative treatment options.
- Distributors of medical devices in the healthcare sector.
Company Profile
Urologix, Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Minneapolis, US. The company is led by CEO Bryon Merade. ULGX has traded publicly since 1996.
Financial Health
Urologix, Inc.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -34.44 places it in the distress zone, a signal of elevated financial risk.
Key Financial Metrics
Return on equity for Urologix, Inc. stands at 232.1%, a gauge of how efficiently it converts shareholder capital into profit. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching.
ULGX Valuation & Market Position
Relative to its peer group, ULGX's quantitative score of 43/100 is below the peer average of 65/100.
ULGX Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in Urologix's future, indicating that key stakeholders believe in the company's growth prospects.
- Community sentiment has shifted positively as discussions around Urologix's innovative treatments gain traction, reflecting increased interest.
- Analysts highlight the company's potential market expansion, particularly in minimally invasive procedures, positioning it favorably against competitors.
- Recent partnerships and collaborations have raised expectations about Urologix's ability to enhance its product offerings and reach new customers.
Bear Case
- Concerns over regulatory hurdles have been prevalent in community discussions, potentially impacting Urologix's ability to bring new products to market.
- Some investors express skepticism about the company's financial health, citing uncertainties in revenue streams and cash flow management.
- Market perception remains cautious due to broader economic conditions, which could affect healthcare spending and investment in Urologix's sector.
- Recent negative sentiment from a segment of analysts suggests doubts about Urologix's competitive edge, especially against larger, established players.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
ULGX Latest News
No recent news available for ULGX.
ULGX Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for ULGX.
Price Targets
Wall Street price target analysis for ULGX.
ULGX MoonshotScore
What does this score mean?
The MoonshotScore rates ULGX 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
ULGX OTC Market Information
ULGX trades on the OTC Other market tier of OTC Markets.
- OTC Tier: OTC Other
Common Questions About ULGX (Healthcare)
What does the AI Score mean for ULGX?
ULGX holds an AI Score of 43/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Urologix, Inc. is a medical device company specializing in minimally invasive treatments for benign prostatic hyperplasia (BPH). Founded in 1991, it focuses on innovative solutions to improve …
What are the key factors to evaluate for ULGX?
Urologix, Inc. (ULGX) holds an AI score of 43/100 (low). presents a unique investment thesis centered on its specialized focus in the urology sector, particularly in treating benign prostatic hyperplasia (BPH). Not financial advice.
How frequently does ULGX data refresh on this page?
ULGX's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven ULGX's recent stock price performance?
Urologix, Inc. (ULGX) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative product offerings tailored for BPH treatment. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider ULGX overvalued or undervalued right now?
Urologix, Inc. (ULGX) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research ULGX before investing?
Before investing in Urologix, Inc. (ULGX), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Why might investors consider adding ULGX to a portfolio?
Key strength of Urologix, Inc. (ULGX): Innovative product offerings tailored for BPH treatment. Weigh rewards against risks and diversify. Not financial advice.
Can I buy fractional shares of ULGX?
Yes, most major brokerages offer fractional shares of Urologix, Inc. (ULGX) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track ULGX's earnings and financial reports?
Urologix, Inc. (ULGX) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for ULGX earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.